Build A Bear Workshop Inc vs ResMed Inc. — how do they compare? Build A Bear Workshop Inc trades at $32.95 (market cap $412.61M), while ResMed Inc. trades at $193.01 (market cap $28.00B). The key difference: ResMed Inc. is far larger — about 67.9× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays the higher dividend (2.8%). Which is the better fit depends on your goals.
| BBW | RMD | |
|---|---|---|
Market Cap | $412.61M | $28.00B |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $293.73 |
52-Week Low | $29.84 | $182.82 |
Enterprise Value | $512.05M | $27.18B |
Dividend Yield | 2.8% | 1.24% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ResMed (RMD) trades at $198.50, down 2.63% on the day, with technical indicators showing a bearish trend near support at $197. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $2.86 versus $2.80 expected, and robust profitability with a 27.44% net margin. Recent strategic moves include the sale of its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets.
The outlook remains positive given analyst consensus targets near $249.57, representing significant upside, though near-term technical weakness and competitive pressures in digital health pose risks. Revenue growth is projected to reach $5.5 billion in 2026, supporting a solid investment case for long-term holders despite current bearish momentum.
Trailing returns across standard periods
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →